<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00433173</url>
  </required_header>
  <id_info>
    <org_study_id>DK71168 (suspended)</org_study_id>
    <secondary_id>NIDDK # 1 RO1 DK071168-01A2</secondary_id>
    <nct_id>NCT00433173</nct_id>
  </id_info>
  <brief_title>Insulin Sensitivity in Men With the Metabolic Syndrome</brief_title>
  <official_title>Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The metabolic syndrome is a medical condition defined by high levels of cholesterol in the&#xD;
      blood, high blood pressure, central obesity (gain in fat around the region of the stomach),&#xD;
      and insulin resistance (body responds less well to insulin). This state of impaired insulin&#xD;
      resistance can lead to type 2 diabetes mellitus, which is one of the most common metabolic&#xD;
      disorders in the U.S. Numerous studies have shown an inverse relationship between insulin&#xD;
      resistance and testosterone levels in men, however, causality has not been established. This&#xD;
      protocol investigates the role of testosterone in modulating insulin sensitivity in insulin&#xD;
      resistant states such as the metabolic syndrome. The hypothesis is that testosterone&#xD;
      administration will improve insulin sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol will address the impact of three months of testosterone (T) therapy on all&#xD;
      components of the metabolic syndrome and the mechanism underlying changes in insulin&#xD;
      sensitivity by analyzing changes in body composition, and detailed studies of fat metabolism&#xD;
      and skeletal muscle. In addition, this protocol will address the role of estradiol (E2) in&#xD;
      mediating the effect of testosterone on insulin sensitivity.&#xD;
&#xD;
      Seventy-two subjects will be enrolled. Study subjects will undergo a screening visit to&#xD;
      assess eligibility after which a baseline metabolic assessment will be performed including a&#xD;
      a fasting oral glucose tolerance test (OGTT) to measure normal glucose and insulin&#xD;
      metabolism, an intravenous glucose tolerance test (IVGTT) to measure insulin sensitivity, MRI&#xD;
      and DEXA scan to assess muscle and body fat distribution, VO2 max test and resting metabolic&#xD;
      rate, and a muscle biopsy to look at how the muscle is affected by insulin and testosterone&#xD;
      (T).&#xD;
&#xD;
      Subjects will then be randomized to one of three 12-week treatment arms, 1) Group 1&#xD;
      (Placebo); 2) Group 2 (Depot GnRH agonist (Zoladex) + Testosterone + placebo); or 3) Group 3&#xD;
      (Zoladex + Testosterone + aromatase inhibitor (anastrozole)). The rationale for this study&#xD;
      design is as follows. Under normal physiological conditions, administration of T leads to a&#xD;
      concomitant increase in estradiol (E2) levels due to endogenous conversion by the aromatase&#xD;
      enzyme system. Therefore, in order to understand the relative roles of T and E2 on insulin&#xD;
      sensitivity, one group of subjects will receive T in conjunction with the aromatase&#xD;
      inhibitor, anastrozole.&#xD;
&#xD;
      At 13 weeks, the entire baseline evaluation including OGTT, IVGTT, resting metabolic rate and&#xD;
      VO2 max, body composition assessment by DEXA and MRI, and muscle biopsy will be repeated.&#xD;
      Subjects will return for a follow up visit four weeks later to measure CBC, T and PSA levels,&#xD;
      to ensure levels are within the normal range.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Primary investigator is taking a leave of absence&#xD;
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin sensitivity</measure>
    <time_frame>at baseline and after 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>glucose metabolism</measure>
    <time_frame>at baseline and after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition VO2 max; resting metabolic rate; muscle biopsy analysis</measure>
    <time_frame>at baseline and after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max</measure>
    <time_frame>at baseline and after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting metabolic rate</measure>
    <time_frame>at baseline and after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>muscle biopsy analysis</measure>
    <time_frame>at baseline and after 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1) Group 1: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intravenous glucose tolerance test</intervention_name>
    <description>The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>IVGTT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone</intervention_name>
    <description>transdermal 7.5 g/per day for 3 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Androgel 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>tablet (per oral) 10.0 mg/ daily 3 months</description>
    <arm_group_label>3</arm_group_label>
    <other_name>arimidex</other_name>
    <other_name>IND# 76,878</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate implant</intervention_name>
    <description>single depot injection 10.8 mg 3 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>aerobic capacity (VO2 Max)</intervention_name>
    <description>This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>muscle biopsy</intervention_name>
    <description>Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergstr√∂m needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>measurement of resting metabolic rate (energy expenditure)</intervention_name>
    <description>Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual energy x-ray absorptiometry</intervention_name>
    <description>Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>DEXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fasting oral glucose tolerance test</intervention_name>
    <description>To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>OGTT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 50-75 yr&#xD;
&#xD;
          -  Diagnosis of the metabolic syndrome defined by the American Heart Association/National&#xD;
             Heart, Lung, and Blood Institute guidelines as the presence of three or more of the&#xD;
             following:&#xD;
&#xD;
               -  Waist circumference &gt; 102 cm&#xD;
&#xD;
               -  Serum triglycerides &gt; 150 mg/dL&#xD;
&#xD;
               -  HDL cholesterol &lt; 40 mg/dL&#xD;
&#xD;
               -  Blood pressure &gt; 130 mm Hg systolic or 85 mm Hg diastolic, or treatment with&#xD;
                  anti-hypertensives&#xD;
&#xD;
               -  Fasting serum glucose &gt; 100 mg/dL&#xD;
&#xD;
               -  Plasma total testosterone level less than 300 ng/dL (1 SD below the mean for&#xD;
                  young healthy men)&#xD;
&#xD;
               -  Stable weight for previous three months (no weight change greater than or equal&#xD;
                  to +/-10 lbs)&#xD;
&#xD;
               -  Normal TSH, prolactin and prostate specific antigen (PSA) levels (&lt;2.5 ng/mL)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  New diagnosis of type 2 diabetes as defined by the ADA criteria: fasting glucose&#xD;
             greater than 126 mg/dL or random blood glucose greater than 200 mg/dL on two&#xD;
             occasions, or on oral hypoglycemic agents&#xD;
&#xD;
          -  Contraindication to stress testing&#xD;
&#xD;
          -  Contraindication to MRI scanning (Central nervous system aneurysm clips; Implanted&#xD;
             neural stimulator; Implanted cardiac pacemaker or defibrillator; Cochlear implant;&#xD;
             Ocular foreign body (e.g. metal shavings); Insulin pump; Metal shrapnel or bullet)&#xD;
&#xD;
          -  History of testicular disorders (i.e. cryptorchidism)&#xD;
&#xD;
          -  History of bleeding disorders (i.e. thrombocytopenia) or baseline hemoglobin levels&#xD;
             less than 12g/dL&#xD;
&#xD;
          -  History of metabolic bone disease (osteoporosis, osteomalacia)&#xD;
&#xD;
          -  History of prostate cancer&#xD;
&#xD;
          -  History of sleep apnea (subjects will also be excluded if at their baseline assessment&#xD;
             they admit to heavy snoring, restless sleep, and/or excessive daytime somnolence)&#xD;
&#xD;
          -  Symptoms of urinary outflow obstruction (i.e. benign prostatic hypertrophy)&#xD;
&#xD;
          -  Illicit drug use or heavy alcohol use (&gt;4 drinks/day)&#xD;
&#xD;
          -  Allergic disorders&#xD;
&#xD;
          -  Current medications (must exclude individuals taking the following medications):&#xD;
&#xD;
               -  Testosterone,&#xD;
&#xD;
               -  Cimetidine,&#xD;
&#xD;
               -  Spironolactone,&#xD;
&#xD;
               -  Ketoconazole,&#xD;
&#xD;
               -  Finasteride,&#xD;
&#xD;
               -  DHEA,&#xD;
&#xD;
               -  Androstenedione,&#xD;
&#xD;
               -  Oral steroids,&#xD;
&#xD;
               -  GnRH analogs&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances J Hayes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2007</study_first_posted>
  <last_update_submitted>March 1, 2010</last_update_submitted>
  <last_update_submitted_qc>March 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Frances J. Hayes, MD</name_title>
    <organization>Massachusetts General Hospital, Boston MA 02114</organization>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>metabolic disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

